ATRX is an X-linked gene of the SWI/SNF family, mutations in which cause syndromal mental retardation and downregulation of a-globin expression. Here we show that ATRX binds to tandem repeat (TR) sequences in both telomeres and euchromatin. Genes associated with these TRs can be dysregulated when ATRX is mutated, and the change in expression is determined by the size of the TR, producing skewed allelic expression. This reveals the characteristics of the affected genes, explains the variable phenotypes seen with identical ATRX mutations, and illustrates a new mechanism underlying variable penetrance. Many of the TRs are G rich and predicted to form non-B DNA structures (including G-quadruplex) in vivo. We show that ATRX binds G-quadruplex structures in vitro, suggesting a mechanism by which ATRX may play a role in various nuclear processes and how this is perturbed when ATRX is mutated.
INTRODUCTION
Although it is known that proteins of the Swi/Snf family are required to facilitate a wide range of nuclear processes (e.g., replication, recombination, repair, transcription), the mechanisms by which they operate in vivo are poorly understood (Flaus et al., 2006) . One such widely expressed protein (ATRX) was first identified when it was shown that mutations in the X-linked gene (ATRX) caused a form of syndromal mental retardation, with multiple developmental abnormalities characteristically associated with a thalassaemia (ATR-X syndrome) (Gibbons et al., 1995) . To date 127 disease-causing mutations have been found, most of which are located in two highly conserved domains of the ATRX protein (Gibbons et al., 2008) . At the N terminus these lie within a globular domain (similar to that found in DNMT3 and DNMT3L, the so-called ADD domain) including a plant homeodomain (PHD), which most probably binds the N-terminal tails of histone H3 (Argentaro et al., 2007) . At the C terminus there are seven helicase subdomains that identify ATRX as a member of the SNF2 family of chromatin-associated proteins ( Figure 1A ). Although many of these proteins have been shown to remodel, remove, or slide nucleosomes using in vitro assays, ATRX is most closely related to a subgroup (including RAD54 and ARIP4) that, despite acting as ATP-driven molecular motors, perform poorly in such canonical assays, suggesting that they have related but different chromatin-associated functions (Xue et al., 2003 and unpublished data) .
Some clues to the role of ATRX in vivo have come from studying its distribution in the nucleus, the proteins with which it interacts, and the effects of mutations. Using indirect immunofluorescence, ATRX is found at heterochromatic repeats, at rDNA repeats, at telomeric repeats, and within PML bodies, which themselves are often associated with heterochromatic structures including telomeres (Gibbons et al., 2000; McDowell et al., 1999; Xue et al., 2003) . Two robust protein-protein interactions have been described. The first occurs with DAXX (Xue et al., 2003) (a protein that is also found in PML bodies), which has been implicated in both pro-and antiapoptotic pathways. The second interaction occurs with HP1a and HP1b, proteins that are widely associated with heterochromatin, including the telomere (Berube et al., 2000) . It has also been shown that mutations in ATRX are consistently associated with alterations in the pattern of DNA methylation at such repeat sequences (rDNA, interstitial heterochromatic repeats, and subtelomeric repeats) (Gibbons et al., 2000) .
Recently, an important link has been established between these observations and more functional studies. First, it has been shown that ATRX and HP1 localize to the telomeres of chromosomes in mouse embryonic stem cells (ESCs) (Wong et al., 2010) . Second, it has been shown that ATRX localizes to telomeres in synchrony with the histone variant H3.3. Using immunoprecipitation it was shown that ATRX and its partner DAXX specifically interact with H3.3, which is found to be associated with both active and inactive genes, regulatory elements, and telomeres (Goldberg et al., 2010) . It has recently been shown that DAXX is an H3.3-specific chaperone (Drané et al., 2010; Lewis et al., 2010) , and in the absence of ATRX, H3.3 is no longer recruited to telomeres whereas recruitment to the interstitial sites that were analyzed appeared to be unaffected (Goldberg et al., 2010) . These observations suggest that ATRX plays an important role in establishing or maintaining the chromatin environment of telomeres and subtelomeric regions where it facilitates histone Table S1 .
(E) Direct mapping of ATRX ChIP-seq sequence reads to mouse simple and interspersed repeats. See Figure S1 for further validation of the specificity of the ATRX ChIP.
replacement with the H3.3 variant (Drané et al., 2010; Lewis et al., 2010) . Although these observations have provided new insight into the potential role of ATRX at heterochromatic regions of the genome, they have not identified the euchromatic targets of ATRX and have not addressed the role of ATRX in regulating gene expression. To date the only human genes whose expression is known to be affected by ATRX mutations lie in the a-globin gene cluster (Gibbons et al., 1991) . Although clearly related to the b-globin cluster throughout evolution, ATRX mutations do not affect b-globin expression. It has been noted that the structure (e.g., GC content, repeat density, gene density), nuclear organization (e.g., nuclear position, relationship to chromosome territory, relationship to heterochromatin), and epigenetic environment (e.g., timing of replication, chromatin modification, DNA methylation) associated with these two clusters are radically different (Higgs et al., 1998) . Most notably the human a-globin cluster lies very close to the telomere of chromosome 16. It has previously been suggested that ATRX is targeted to specific regions of the genome defined by their genomic organization and/or chromatin structure. Thus mutations in ATRX may affect one type of chromosomal region (e.g., containing the a-globin genes) but not another (e.g., containing the b-globin genes).
Here we have established the genome-wide distribution of the ATRX protein in both mouse and human cells. We have confirmed that ATRX binds directly to mouse telomeres and also shown that ATRX is enriched at the telomeres and subtelomeric regions of human chromosomes. Chromatin immunoprecipitation (ChIP) sequencing identified 917 targets in primary human erythroid cells (in which the globin genes are expressed) and 1305 targets in mouse ESCs. The most prominent feature of the targets in both human and mouse is the presence of variable number tandem repeats (VNTRs), which in many (but not all) cases are G and C rich and contain a high proportion of CpG dinucleotides. Of particular interest we show that, when ATRX function is compromised in ATR-X syndrome, the degree of perturbation in gene expression is related to the size of the TR, and this may lead to monoallelic expression. These findings explain the variable phenotypes seen in patients with identical ATRX mutations and provide a new mechanism underlying variable penetrance. A common theme shared by telomeres and many of the subtelomeric targets of ATRX is their potential to form G-quadruplex (G4) DNA structures. Here we show that ATRX binds G4 DNA in vitro, suggesting a common mechanism by which ATRX may influence a wide range of nuclear processes in the telomeric, subtelomeric, and interstitial regions of mammalian chromosomes.
RESULTS
Validation of an ATRX ChIP Protocol with rDNA as a Target Domain structure, interaction partners, and biochemical activity currently implicate ATRX in the regulation of transcription via a physical interaction with chromatin. To date, ATRX has been implicated in histone H3.3 deposition at telomeres, but little is known about ATRX function away from telomeres because no direct ATRX target genes have been described. To address this, an ATRX ChIP assay was developed using the ribosomal gene loci (rDNA) as the first candidate targets. The rDNA loci were chosen because immunofluorescence studies have previously shown that, in mitotic cells, ATRX is consistently found on the short arms of the acrocentric chromosomes in human colocalizing with the rDNA loci (McDowell et al., 1999) ; rDNA also becomes hypomethylated at CpG dinucleotides in primary peripheral blood mononuclear cells (PBMCs) from patients with ATR-X syndrome (Gibbons et al., 2000) .
ChIP analysis was performed with an ATRX antibody that recognizes a C-terminal epitope only present in the full-length ATRX isoform ( Figure 1A ). Western blot was used to confirm that this antibody immunoprecipitates ATRX with detection using an independent antibody ( Figure 1B) . ATRX ChIP enrichment at rDNA was measured in primary erythroblasts and Hep3B cells ( Figure 1C ). Consistent with its ubiquitous expression profile, ATRX binds rDNA in both cell types tested. It was of interest that the maximal binding of ATRX occurs at the transcribed region of the locus that is very rich in G and CpG nucleotides. These observations confirm the specificity of the ATRX C-terminal antibody, validate the ChIP assay, and identify the ribosomal genes as direct ATRX targets.
ATRX Binds G-Rich Telomeric and Subtelomeric
Repetitive DNA Having validated the ATRX ChIP protocol, we next addressed whether, in addition to rDNA, other putative targets (heterochromatic repeats) identified by indirect immunofluorescence were similarly bound by ATRX. To accomplish this, we took a ChIP-seq approach using Illumina high-throughput, short read sequencing to analyze primary human erythroid cells and mouse ESCs.
ATRX ChIP DNA from human primary erythroid cells was sequenced alongside sonicated input DNA as a control. The short read mapping protocol used for ChIP sequencing (see below) routinely discards nonunique genomic matches, precluding analysis of direct binding to repeat sequences. To overcome this, we interrogated the ATRX ChIP read library for perfect sequence matches to a variety of tandem and interspersed repeat sequences. As a negative control, we used ChIP-seq data for YY1 and SCL, transcription factors that have no known role at heterochromatic repeats. YY1 and SCL ChIP DNA both showed low enrichment of telomeric and nontelomeric satellite sequences ( Figure 1D and Table S1 available online). ATRX ChIP DNA showed striking enrichments for the G-rich telomeric (TTAGGG) n repeats ($16-fold relative to input DNA) and telomere-associated repeats ($10-fold relative to input) ( Figure 1D and Table S1 ). Similar results were obtained from the analysis of ChIP-seq data from mouse ESCs ( Figure 1E and Table S1 ). Further confirmation of the specificity of the ATRX ChIP was demonstrated by showing that ATRX enrichment was abolished when ChIP was performed in mouse ESCs in which full-length ATRX was knocked out ( Figure S1 ).
These data therefore show that previously described immunofluorescence studies reflect the binding of ATRX to telomeric and subtelomeric repeat sequences. The presence of ATRX at the subtelomeric TAR1 repeats is consistent with previous observations that DNA methylation at subtelomeric repeats is altered in patients with ATR-X syndrome (Gibbons et al., 2000) .
Genome-wide Targets of ATRX Include CpG Islands and G-Rich Tandem Repeats
Having established that ATRX binds G-rich repetitive elements associated with rDNA, telomeres, and subtelomeric repeats, ATRX ChIP and input sequence reads were aligned to the genome if five or fewer matches were detected (allowing for three base-pair mismatches). Peak calling was performed on the ATRX ChIP-seq alignments using an input correction penalty to deplete peaks overlying enrichments of input reads. The input correction penalty effectively eradicated many peaks overlying DNA where there were differences in copy number between the reference genome and the sequenced genome (e.g., at pericentromeric satellite DNA).
Using these criteria in primary human erythroid cells we identified 917 ATRX-binding sites genome-wide. The ChIP enrichment at 14 sites (chosen to represent the different classes of targets discussed below) was validated using Q-PCR. ATRX binding at most of these sites was enriched above background levels 10/14 (false discovery rate 4/14; Figure S2A ). Of the 917 ATRX peaks called, approximately a third (324) were intergenic, a third were present at promoter regions (326), and a third were in the bodies of genes (267) Each column represents the total number of ATRX peaks within nonoverlapping 1/500 divisions of all chromosome arms. The zoomed panels show the telomeric region, overlayed with the mean %G+C content of all tandem repeats throughout the same regions, for the respective human and mouse chromosomes. The sharp peak of subtelomeric targets in mouse represents clusters of (TTAGGG) n adjacent to the telomeres of a subset of mouse chromosomes. See also Figure S2E for the distribution of TRs and Refseq genes near telomeres. See also Figure S2A for validation of targets by Q-PCR, Figure S2B for examples of ATRX-binding sites, Figure S2D for trinucleotide content of DNA sequence underlying peaks, Figure S3A for histone modifications associated with peaks, and Figure S3B for histone H3.3 distribution associated with ATRX peaks.
examined for overlap with annotated genomic sequence features (Figures S2B and S2C) . Two striking observations arise from this analysis: first, irrespective of location relative to genes, human ATRX-binding sites commonly coincide with CpG islands ( Figure 2B) ; second, the predominant sequence feature that ATRX binds in gene bodies and intergenic regions is tandem repetitive DNA ( Figure 2B and Figure S2C ). Analysis of ATRX binding in mouse ESCs (Figure 2A ) identified a larger number of ATRX targets (1305) and showed a similar enrichment at TRs but less so at CpG islands ( Figure 2B ) (which occur much less frequently in the mouse genome) (Waterston et al., 2002) . As the tandem repetitive ATRX targets at rDNA and telomeres are G rich, we reasoned that this might be a common property of other ATRX-bound TRs. To test this we calculated the tri-nucleotide sequence content of ATRX-bound tandem repetitive targets. ATRX-bound TRs in both mouse and human are significantly enriched for G and C and CpG, and they are depleted in A-and T-containing trinucleotides relative to randomly selected control repeats ( Figure S2D and data not shown).
These findings are consistent with the observation that in human cells, many ATRX-bound promoters are associated with CpG islands. Genome-wide analysis (in human) showed that there are no chromatin modifications consistently associated with binding of ATRX. Chromatin marks found at the promoter and intragenic and intergenic binding sites show the characteristic chromatin modifications associated with such features ( Figure S3A ). Together the data suggest that ATRX interacts predominantly with G and C and CpG-rich sequences contained within TRs and promoters.
The Distribution of ATRX-Binding Sites Differs between Human and Mouse, Reflecting the Different Distributions of G-Rich Tandem Repeats Initial analysis of the human ChIP-seq data suggested that ATRX targets may be clustered at subtelomeric regions of the genome ( Figure 1D ). This was confirmed when the proportions of ATRXbinding sites were plotted as a function of their distance from the nearest telomere (pooling data for all telomeres) ( Figure 2C ). However, it has previously been shown that in humans, GC content, CpG density, G-rich minisatellites, and gene density are all increased in subtelomeric regions of the genome, and this was confirmed here ( Figure 2C and Figure S2F ). In fact, the distribution of ATRX targets in humans appears largely to reflect the increase in GC content and G-rich TRs observed toward telomeres rather than increased gene or general TR density ( Figure 2C and Figure S2E ).
To explore this further, we compared the data from human with those from mouse, a species with less extremes of GC content and a different distribution of G-rich repeats (Waterston et al., 2002) . In mouse, the GC content of TRs is not increased toward telomeres but is more evenly distributed across each chromosome ( Figure 2C ). Although the majority of mouse targets are associated with CpG islands or TRs (as in human), the mouse ATRX targets are less concentrated at telomeres ( Figure 2C ). This more even distribution of ATRX targets in mouse is consistent with the more even distribution of GC content and G-rich repeats in mouse compared to human ( Figure 2C ). These findings focus attention on the fact that ATRX appears to bind many G-rich TRs in different chromosomal environments rather than genes within subtelomeric regions per se.
Analysis of H3.3 Distribution in the Absence of ATRX
Telomeres are a site of rapid nucleosomal turnover as demonstrated by the incorporation of histone H3.3 (Goldberg et al., 2010) . Furthermore, it has recently been shown that ATRX recruits the histone H3.3-specific chaperone DAXX and facilitates H3.3 deposition at telomeres and pericentric DNA (Drané et al., 2010; Lewis et al., 2010) . In order to see whether H3.3 colocalized with ATRX at its target sequences (predominantly TRs, Figure 2B ), data for the H3.3 distribution in mouse ESCs (Goldberg et al., 2010) were reanalyzed to determine the distribution of H3.3 at ATRX-binding sites ( Figure S3B ). Peaks of H3.3 are observed at genic and intergenic ATRX sites. ATRX has previously been shown to be required for H3.3 deposition at telomeres but not at promoters and transcription factor-binding sites (Goldberg et al., 2010) . In order to see if the H3.3 distribution at these sites is dependent on ATRX, the patterns of H3.3 for Atrxflox and Atrxnull mouse ESCs were compared. The distribution of H3.3 is only subtly perturbed at ATRX-binding sites in gene bodies and intergenic sites ( Figure S3B ) with a slight diminution of the peak and increased signal in the adjacent sequence. If ATRX is required for H3.3 incorporation it may be only at a subset of these targets.
Analysis of Expression of ATRX Targets when ATRX Is Mutated
Although we initially identified the human ATRX targets in erythroid cells, because many of the affected genes are widely expressed, we compared their expression in Epstein-Barr virus (EBV)-transformed lymphocytes from normal individuals (n = 19) with expression in EBV cells from individuals harboring natural mutations in the ATRX gene (n = 23). Twenty ATRX targets (expressed in EBV-transformed lymphocytes) were chosen for analysis, including 9 ATRX promoter-binding targets and 11 tandem repetitive gene body targets. Four ATRX targets were significantly altered in expression in ATR-X patients relative to normal controls: NME4, SLC7A5, and RASA3 were downregulated, whereas GAS8 was upregulated (Figure 3) . Interestingly all four novel targets contained tandem repetitive ATRX-binding sites, whereas none of the nonrepetitive, promoter-binding site target genes was affected. These data suggest that when ATRX alters gene expression, this involves an interaction with TRs associated with its target genes.
ATRX Exerts an Effect on Target Gene Expression via an Interaction with G-Rich Repeats
To examine the role of ATRX in regulating gene expression in detail, we analyzed the subtelomeric region of chromosome 16 (16p13.3), which contains two ATRX targets (a-globin and NME4), both of which are downregulated in ATR-X syndrome. ChIP-seq analysis of this area was confirmed by ChIP-chip analysis ( Figures 4A and 4B and Figure S4A ). With this approach, three consistent peaks of ATRX binding were seen in primary erythroid cells. A small but reproducible enrichment was seen at the probe closest to the telomere (telomeric repeats were not included on the array). In erythroid cells, a broad region of enrichment was seen across all the a-like globin genes with maximum binding just upstream of the HBM globin gene. A third peak was seen at the gene encoding a nucleoside kinase, NME4 ( Figure 4A and Figure S4A ). When we used Q-PCR ( Figures S4B  and S4C ), we noted that all peaks of ATRX binding localized at or very close to regions of G-rich tandemly repetitive DNA. The subtelomeric peak shows an enrichment lying $150 bp from the start of the telomeric satellite repeats (TTAGGG) n ( Figure S4B ). The maximum peak of binding in the a-globin locus lies within a VNTR (CGCGGGGCGGGGG) n 1 kb upstream from the HBM promoter, called jz VNTR (Figures S4B and S4C) . The peak at NME4 is centered on an imperfect VNTR (CCCGG CCCCCCCA) n within the first intron of the gene ( Figures S4B  and S4C ).
It has been previously shown that expression of RNA from the HBA1 and HBA2 globin genes is downregulated in patients with the ATR-X syndrome (Wilkie et al., 1990) . However, maximal ATRX binding occurs not at the HBA genes but in close proximity to the HBM and NME4 genes. We therefore took an unbiased approach using RT-PCR to measure expression of all 16 genes in the 500 kb region in normal individuals (n = 19) and those proven to have ATR-X syndrome (n = 20) ( Figure 4C ). Globin gene expression was analyzed using cDNA derived from erythroid cells, and other genes were analyzed using cDNA from EBV cell lines (nonglobin mRNAs are of very low abundance in erythrocytes). The most consistently and severely downregulated genes (HBM and NME4) were those associated with the greatest peaks of ATRX enrichment ( Figures 4B and 4C) . It was of interest that other significantly downregulated genes (HBA2, HBA1, HBQ, and DECR2) lie adjacent to these severely affected genes. Furthermore, the degree of downregulation of each a-like globin (HBM > HBA2 = HBA1 > HBQ) gene is related to its proximity to the major peak of ATRX binding 1 kb upstream from the HBM gene.
This observation explains the a thalassaemia seen in ATR-X syndrome and why a-globin and not b-globin expression is perturbed, as only the former locus is associated with G-rich VNTRs (Higgs et al., 1998) .
The Perturbation in Gene Expression Is Related to the Size of the Associated Tandem Repeat
In ATR-X syndrome, a-globin RNA expression is often downregulated, but affected individuals show different degrees of repression ( Figure 4C ). This gives rise to different degrees of a thalassaemia and is reflected by varying proportions of red cells containing HbH inclusions, ranging from 0%-30% (Gibbons et al., 2008) . Importantly, such variation is seen between individuals with the same ATRX mutation ( Figure S5A ) and occurs both within and between affected families. However, for any individual, the level of HbH is relatively constant throughout life. If the downregulation of a-globin expression in ATR-X syndrome resulted from a negative effect due to a TR then one might predict that the effect would be more extreme when the repeat is increased in size. The jz VNTR is highly polymorphic. The size of the TR alleles was measured in 43 ATR-X individuals, and the average size in an individual was plotted against the level of HbH inclusions observed. A significant correlation (r value = 0.58; p = 0.0002) was seen between the level of inclusions (reflecting the degree of a thalassaemia) and the size of the TR ( Figure 5A and Figure S5B ). jz VNTR lies within a block of linkage disequilibrium ( Figure S5C and Table S3 ); polymorphisms within this block also show a correlation with the number of cells containing HbH inclusions. In contrast with jz VNTR, another VNTR within this block, 3 0 HVR, showed a low correlation between size and the severity of a thalassaemia ( Figure S5B ). Given the rapid evolution of VNTRs relative to the background haplotype, the strong correlation associated with the jz VNTR strongly supports the A) Microarray analysis (black bars) of ATRX ChIP DNA enrichment across the 500 kb terminal region of chromosome 16p containing the a-globin genes and surrounding ubiquitously expressed genes. ATRX ChIP DNA from erythroblasts (n = 4), fibroblasts (n = 1), and Hep3B (n = 2) cells were analyzed as well as erythroblasts immunoprecipitated with control IgG (n = 2). Representative data are shown. See Figure S4A for full dataset for erythroblasts. (B) ChIP-seq analysis of erythroblast ATRX ChIP and input DNA using Illumina short-read sequencing. Graphs are a 50 bp sliding window of mapped reads. Black bars show peak calls. (C) Q-PCR analysis of gene expression across the a-globin gene locus in ATR-X patient (n = 20) and normal control (n = 19) cDNAs (from erythroid cells for the globin genes or lymphoblastoid cells for other genes). Expression was measured relative to GAPDH and the mean expression values for the normal controls were set to 100%. Red bars represent means of ATR-X patient expression and p values are for a two-tailed t test. See Figures S4B and S4C for validation of targets by Q-PCR and mapping of peaks to G-rich VNTRs.
proposal that it is directly responsible for the variability seen in the level of HbH inclusions.
The effect of TR size was further examined at the NME4 locus. Again the TR is highly polymorphic; in this case the presence of an expressed A/G single-nucleotide polymorphism (SNP) allowed us to determine the effect of the TR size on allele-specific expression. In ATR-X cases informative for the expressed SNP, the most downregulated allele is always in cis with the larger TR ( Figures 5B and 5C ). In some cases the expression was monoallelic ( Figure 5D ).
ATRX Targets
Have the Potential to Form G4 DNA, and ATRX Binds to G4 DNA Structures Tandem repetitive sequences can take up a range of non-B DNA conformations (reviewed in Bacolla and Wells, 2009 ). G-rich sequences such as telomeres, rDNA, G-rich TRs, as well as CpG islands can form abnormal DNA structures in vitro referred to as G-quadruplex (G4) under physiological conditions (reviewed in Lipps and Rhodes, 2009 ). These structures form in G-rich sequences that contain four tracts of at least three guanines separated by other bases and are stabilized by G-quartets that form between four DNA strands held together by Hoogsteen hydrogen bonds. Such structures are particularly likely to form when DNA becomes single stranded, for example during replication and transcription, and may interfere with these nuclear processes.
To explore the possibility that ATRX targets might form G4 structures in vivo, a genome-wide bioinformatic analysis using Quadparser was performed to identify regions that have the potential to form G4 DNA (Huppert and Balasubramanian, 2005) . Fifty percent of ATRX peaks were found to overlap with putative quadruplex sequences (PQSs) ( Figure 6A ). Given the difficulty sequencing G-rich repeats and their consequent contraction in the reference genome, it is possible that PQSs are under-called in this analysis.
The potential for an ATRX-binding site to form G4 was further examined using circular dichroism (Paramasivan et al., 2007) . The NME4 TR is predicted to form G4. A 31 bp oligonucleotide Figure S5A for variable severity of a thalassaemia in ATR-X syndrome, see Figure S5C and Table S3 for a-globin locus haplotype and linkage analysis.
(B) Q-PCR-based allelic discrimination assay was used to determine the ratios of each NME4 allele present in both genomic DNA and cDNA from controls and ATR-X patients. The y axis is the ratio of A:G allele (SNP rs14293), shown on a logarithmic scale. For control cDNA samples, the ratio of A:G allele expression is 0.70 to 1.30, mean = 1.0, n = 13. For ATR-X cDNA samples, the ratio of A:G allele expression is 0.24 to 2.37, mean = 0.84, n = 17. F-test p value = 5.74 3 10 À5 . For the green datapoint, the larger VNTR is linked to the G allele; for the red datapoints, the larger VNTR is linked to the A allele. For the blue datapoint, alleles could not be discriminated based on VNTR size. (C) Schematic representation of the exon/intron structure of NME4. White boxes represent exons. PCR amplicons are shown as generated from genomic DNA and cDNA. The presence of a polymorphic XhoI site generated by SNP rs14293 in NME4 exon 4 is shown, which allows allelic discrimination by PCR amplification followed by an XhoI restriction digest assay, the restriction site being present in the G allele and abolished in the A allele. (D) Results show monoallelic expression of NME4 in two individuals with ATR-X syndrome.
representing the repeat unit of the NME4 TR was incubated in conditions that favor G4 DNA formation. The circular dichroism spectrum was obtained ( Figure 6B ). A positive ellipticity maximum was observed at 260 nm and a negative ellipticity minimum at 240 nm, consistent with a parallel G4 form. Another smaller ellipticity maximum at 295 nm suggested the coexistence of an antiparallel G4 form. A further six ATRX TR target sequences were analyzed by circular dichroism (CD); the spectrographs were consistent with the formation of G4 including one sequence that was not predicted by Quadparser to form G4 ( Figure S6A and Table S4 ). Finally, we used a gel-shift assay to test whether ATRX could interact with G4 DNA in vitro. A G-rich oligonucleotide was preformed into G4 DNA, labeled, and incubated with full-length recombinant ATRX ( Figure 6C ). ATRX specifically bound to the G4 structure and no shift was observed when the structure was denatured by boiling before adding to the binding reaction. Further, binding to the formed G4 structure can be competed by a molar excess of unlabeled formed G4 but is less effectively competed by the denatured G4 oligonucleotide or another structured nucleic acid (Holliday junction) ( Figure 6C ), indicating that ATRX binds the G4 structure rather than the sequence per se. These data indicate that ATRX may be recruited to telomeres, other G-rich TR, and G-rich nonrepetitive DNA and interact with G-quadruplex DNA.
DISCUSSION
Genome-wide analysis has shown that in euchromatin the predominant targets of ATRX are sequences containing VNTRs. Many of these are G and C rich with a high proportion of CpG dinucleotides. These observations explain why ATRX mutations affect the a-globin cluster but not the b-globin cluster and cause a thalassaemia. The a cluster lies in a GC-rich subtelomeric region containing a high density of CpG islands and G-rich TRs that we have now shown are targeted by ATRX. The b-globin cluster has none of these features. It may also explain why in mouse there are a number of imprinted genes (that are also associated with tandemly repeated sequences) whose expression is affected by downregulation of ATRX (Kernohan et al., 2010) .
The relationship between ATRX, VNTRs, and gene expression is clearly illustrated by the fact that of the targets whose expression was analyzed, all affected genes were associated with TRs. Furthermore, at some target genes, the degree by which gene expression is altered is directly related to the size of the VNTR, and in the case of one gene examined in detail (NME4), this can result in monoallelic expression. This provides an explanation for a long-standing question of why individuals with identical ATRX mutations have variable degrees of a thalassaemia. As they all have the same mutation and apparently wild-type a-globin gene clusters, one would have predicted that they would downregulate the a-globin genes to the same extent. The highly significant relationship between the effect of the ATRX deficiency and the natural variation in the VNTR specifically explains the variable penetrance of ATR-X syndrome but more importantly identifies a new mechanism that might underlie many other genetic traits with similar variable penetrance.
A clearly demonstrated but unexplained phenomenon is that, in the absence of ATRX, expression of the target gene lying closest to an ATRX peak is the most severely perturbed. However, adjacent cis-linked genes (up to 10 kb downstream of the peak) are also affected. For example, although there is enrichment of ATRX across the entire a-globin gene cluster, the main peak lies close to HBM and is associated with the G-rich TR in the HBZ pseudogene. HBM is severely downregulated, but HBA1 and HBA2 are also downregulated to a lesser degree. Similarly, at NME4, although this gene is severely downregulated, the adjacent gene (DECR2) is also affected but to a lesser degree. It appears that ATRX normally binds to these G-rich TRs; in the absence of ATRX, the repeats at these loci now exert a repressive influence on transcription that spreads for some distance from the repeat. At present it is not clear how ATRX might recognize such repeat sequences, but one possibility is that they form unusual, non-B DNA structures in vivo, and in the case of the G-rich repeats these may take the form of G-quadruplex structures. Such structures have been demonstrated in vitro using repeats from telomeres, rDNA, G-rich minisatellites, and CpG-rich promoters (all ATRX targets), and half of the ATRX targets identified here are predicted to form G4 DNA. In keeping with the observations described above, the longer the repeat the more likely it is to form G4 DNA (Ribeyre et al., 2009 ). Such structures have been notoriously difficult to identify in vivo, but the strongest evidence for their existence is at telomeres where it has been suggested that G4 structures may form during DNA replication and transcription (Lipps and Rhodes, 2009) . It is therefore of interest that ATRX is recruited to telomeres during replication and that downregulaton of ATRX by RNAi provokes a DNAdamage response (marked by gamma-H2AX) at telomeres during S phase (Wong et al., 2010) . Downregulation of ATRX expression is also associated with an altered expression of telomere-associated RNA (Goldberg et al., 2010) . Both of these observations would be consistent with ATRX playing a role in recognizing and/or modifying G4 structures at telomeres and by implication at other G-rich TRs in vivo. Nevertheless this is not the only factor determining the localization of ATRX, as at A/T-rich pericentric heterochromatin, the recruitment of ATRX depends on the presence of H3K9me3 (Kourmouli et al., 2005) .
A role for ATRX at G-rich repeats may also be linked to the recent observation that ATRX is required for the incorporation of the histone variant H3.3 at telomeric repeats (Drané et al., 2010; Goldberg et al., 2010; Lewis et al., 2010) . H3.3 may be incorporated into chromatin in a replication-independent or replication-dependent manner and has typically been found at actively transcribed regions of the genome and regions of inherent nucleosome instability where there is a rapid turnover of histones during interphase (Schneiderman et al., 2009) . TRs with a propensity to form abnormal DNA structures are likely to be regions of rapid nucleosome turnover. An appealing hypothesis, therefore, is that ATRX influences gene expression by recognizing unusual DNA configurations at TRs and converting them to regular forms in part by facilitating incorporation of H3.3. Consistent with this we find that H3.3 is found at genic and intergenic ATRX-binding sites, the majority of which are TRs. However the distribution of H3.3 is only subtly perturbed at these sites when ATRX is disrupted. One possibility is that there is a critical requirement for ATRX at a subset of TRs (such as telomeres), whereas at other sites, other proteins can intervene. Future studies will focus on determining the role of ATRX in H3.3 deposition at specific sites.
The role of ATRX may be to recognize unusual forms of DNA and facilitate their resolution in several contexts. In the absence of ATRX, G4 forms may persist and affect many nuclear processes including replication, transcription recombination, and repair.
EXPERIMENTAL PROCEDURES Western Blotting
For ATRX western blotting, the mouse monoclonal 39c (McDowell et al., 1999) and rabbit polyclonal H-300 (Insight Biotechnology sc-1540) were used at 1:10 and 1:1000 dilutions, respectively. 23c and 39f recognize an epitope within ATRX and ATRXt N-terminal to the ADD domain, and H-300 recognizes a C-terminal epitope within 2193-2492 of full-length ATRX only.
Immunopurification Nuclear extracts were prepared from wild-type lymphoblastoid cells as previously described (Dignam, 1990) and incubated overnight at 4 C with H-300 antibody crosslinked to protein A-Sepharose. The beads were washed four times with 20 mM HEPES (pH 7.9), 0.5M KCl, 0.2 mM EDTA, 0.1% Tween, 0.5 mM DTT and immunoprecipitated protein eluted with 0.1 M glycine (pH 2.5), then neutralized with 1 M KHPO 4 . A mock immunopurification was performed as a control in the same way using normal rabbit IgG (Santa Cruz sc-2027) crosslinked to protein A.
Chromatin Immunoprecipitation ATRX chromatin immunoprecipitation was performed according to a published method (Lee et al., 2006) with the following modifications. Cells were fixed with 2 mM EGS (Pierce 26103) for 45 min at room temperature in PBS. Formaldehyde was then added to 1% for 20 min and quenched with 125 mM glycine. Chromatin was sonicated to under 500 bp and lysates were immunoprecipitated with 40 mg ATRX H300 (Insight Biotechnology sc-15408) antibody or rabbit IgG control (Dako X0903). DNA was precipitated with 20 mg of carrier glycogen and quantitated using a Qubit fluorimeter (Invitrogen).
Real-Time Q-PCR
Real-time Q-PCR validation of ChIP-seq peaks was performed using SYBR green mastermix (Applied biosystems 4309155) or using Taqman probes with a 23 Taq mastermix (Applied Biosystems 4304437). SYBR green primers (Table S2) were designed using Macvector software and tested by running a five point, 8-fold serial dilution of genomic DNA to obtain a standard curve with r 2 > 0.99. PCR products were analyzed by melting curve and 3% agarose gel electrophoresis. Taqman probes were designed using Primer Express (Applied Biosystems). ChIP enrichments were determined relative to a 3 point dilution series of input DNA and normalized relative to GAPDH enrichment.
Cell Culture
Human primary erythroblast cultures were prepared using a two-phase liquid culture system according to a published protocol (Fibach et al., 1991) . HbH inclusions were detected in peripheral blood from ATR-X patients as previously described (Gibbons et al., 1992) . Consent was obtained according to standard ethics approval guidelines.
Microarray
Fluorescently labeled ChIP and input DNA was analyzed with a custom tiled microarray covering the subtelomeric region of human chromosome 16p as previously describe (De Gobbi et al., 2007) .
Gene Expression Analysis RNA was extracted using Tri-reagent (Sigma) and quality checked by microfluidics separation using a 2100 Bioanalyser with an RNA 6000 nano kit (Agilent 5067-1511). One microgram was reverse transcribed with Superscript III (Invitrogen). Real-time RT-PCR was performed using commercial Taqman assays and custom assays. Primer sequences and product codes are listed in the Extended Experimental Procedures.
High-Throughput Sequencing and Peak Analysis
See Extended Experimental Procedures.
Allelic Discrimination
The ratio of allele-specific transcripts was ascertained with real-time technology, using an assay designed by Applied Biosystems (Table S2 ). In brief, a single amplicon was used, which in combination with two probes, each specific for one nucleotide of the polymorphism and labeled with a different fluorophore, allowed quantitation of each species. A standard curve with known ratios of A:G alleles was used to ensure specificity and quantitativeness of the assay, and results were confirmed with pyrosequencing (data not shown). Monoallelic expression is demonstrated with a restriction enzyme digest assay. The genomic PCR product is 846 bp, of which the G allele generates fragments of 581 bp and 265 bp when digested with XhoI. The cDNA PCR product is 854 bp, of which the G allele generates fragments of 563 bp and 291 bp when digested with XhoI. The A allele is undigested by XhoI in both cases.
VNTR Size Measurement jz VNTR allele lengths were measured in 43 ATR-X patients with a thalassaemia by PCR and agarose gel electrophoresis. PCR was performed in 16.6 mM (NH 4 ) 2 SO 4 , 67 mM Tris-HCl (pH 8.8), 10% DMSO, 10 mM Beta mercaptoethanol, 125 mM dNTP, 0.83 mM MgCl 2 , 0.7 M Betaine, 0.3 ml platinum Taq (Invitrogen), 250 nM primers 154505F/155293R (Table S2) , and 100 to 400 ng genomic DNA in a 60 ml reaction volume. 3 0 HVR allele sizes were measured by radio-labeled Southern blotting using AluI digested genomic DNA and a probe from pa3 0 HVR.64 derived from genomic fragment Chr16:175999-177279. VNTR sizes were determined with a Typhoon 9400 Variable Mode Imager and ImageQuant TLv2005 software.
Circular Dichroism Analysis
An oligonucleotide containing the repeat found within the VNTR of intron 1 of NME4 (CCGGGGTGGGGGTGGGGGTGTGGGGGGGTGA) was diluted to 2 mM in 20 mM Tris HCl (pH 8) and 5 mM NaCl, heated to 95 C for 10 min then slowly cooled. CD analysis was performed as previously described using a Jasco 810 CD spectrometer (Giraldo et al., 1994) .
G4 Gel Shifts
G4 DNA was formed using oligonucleotide OX1-T (containing the Oxytrichia telomeric repeat sequence) and its structure confirmed as previously described (Sun et al., 1998) . A Holliday junction structure was formed as previously described (Bachrati and Hickson, 2006) . All DNA substrates were gel-purified prior to use. G4 DNA was labeled with [g-32 P]ATP using T4 polynucleotide kinase, and unincorporated nucleotides were removed using a Sephadex G50 column. Where indicated the G4 probe was boiled for 10 min and quenched on ice to denature the G4 structure. Binding reactions (10 ml volume) contained 2 fmol of 32 P-labeled G4 DNA, full-length rATRX protein as indicated (0, 20, or 40 fmol), 6 fmol T 25 oligonucleotide to minimize nonspecific binding in a buffer containing 33 mM Tris acetate (pH 7.9), 66 mM Na acetate, 1 mM MgCl 2 , 100 mg/ml BSA, and 1 mM DTT. Where indicated, unlabeled competitor DNA (G4, denatured G4, or Holliday junction) was added to the reaction at 4-fold molar excess. Reactions were incubated on ice for 30 min. To each reaction 1 ml of 50% glycerol was added and samples were loaded onto a 5% acrylamide gel and electrophoresed in 0.5 3 TBE at 5 V/cm for 4 hr at 4 C. The gel was dried on Whatman filter paper and visualized by autoradiography.
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